AblaCare Procedure

#1 Cause Of Female Infertility

PCOS is a leading cause of female-factor infertility. Over 10% of women are affected and many of them will actively seek fertility treatment. Existing treatment options for these women are unfortunately not always effective: 40% of patients fail to become pregnant on 1st line treatment, and further options bear significant costs, challenges, and risks.

AblaCare is developing a Device and Procedure for the treatment of PCOS-related infertility, to restore ovarian function & natural cycles

Building on a Demonstrated Procedure
AblaCare's approach, Ovarian Rebalancing, improves upon the clinical success of Laparoscopic Ovarian Drilling (LOD) to transform it into an ultrasound-guided procedure. The Procedure builds on numerous positive outcome studies on the safety, short- and long-term efficacy of Laparoscopic Ovarian Drilling (LOD), which lacked dedicated technology.
Ultrasound Procedure
Adapted to Your Practice
Our approach leverages an established procedure to access the ovary: ultrasound-guided transvaginal egg retrieval (used routinely for IVF). The AblaCare Procedure can be performed in the fertility clinic setting using the same minimally invasive, transvaginal access commonly used by fertility physicians. The AblaCare Procedure takes under 1 hour to complete, without the need for general anaesthesia.
Designed for Safety
The AblaCare System uses controlled, bipolar radiofrequency energy to locally destroy ovarian tissue and correct the hormonal imbalances of PCOS patients. The System is designed to enable physicians to safely treat patients, in a more controlled approach than with LOD. Key safety features include:
  • Transvaginal, incision-free procedure
  • Echogenic needle for optimal visualization
  • Catheter anchors into ovary
  • Custom radiofrequency generator with tailored safety cutoffs
AblaCare Device
Learn about our ongoing Clinical Trial

Our First-In-Woman feasibility Trial, ULTRA, is studying the safety and effectiveness of the AblaCare Procedure, in women with PCOS-infertility.

Patients with the following criteria may qualify to participate in the study:
- Adult patient diagnosed with PCOS
- Having failed first-line pharmacological treatment (clomiphene citrate, metformin, letrozole)

This multicenter, prospective trial is ongoing in 3 European geographies: France, Belgium, and the UK.

CAUTION: Investigational device, not currently available for sale.